Captopril + Potassium

What is happening. Captopril, like other ACE inhibitors, reduces aldosterone secretion and promotes renal potassium retention, raising serum potassium. Adding a potassium supplement (or potassium-containing salt substitutes) can produce additive hyperkalemia, which may cause muscle weakness, paresthesias, and potentially dangerous cardiac arrhythmias. Risk is greatest in patients with renal impairment, diabetes, heart failure, the elderly, and those also taking potassium-sparing diuretics.

Mechanism. ACE inhibition decreases angiotensin II and therefore aldosterone, reducing renal potassium excretion. Supplemental potassium adds to this retained pool, producing additive hyperkalemia. Dose separation does not mitigate this pharmacodynamic effect.

Recommendation. Avoid routine potassium supplements and potassium-based salt substitutes unless specifically prescribed and monitored. If potassium is clinically necessary, use under medical supervision with periodic serum potassium and renal function checks. Report symptoms such as muscle weakness, numbness, or palpitations.

What is happening. Potassium supplements or potassium-containing salt substitutes can cause hyperkalemia with Captopril.

Mechanism. Renin-angiotensin system blockade reduces aldosterone-mediated potassium excretion.

Recommendation. Avoid unsupervised potassium supplementation; check potassium and kidney function after initiation, dose changes, or illness.